Serum galectin-3 level in systemic sclerosis

scientific article published on 3 August 2013

Serum galectin-3 level in systemic sclerosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10067-013-2346-8
P698PubMed publication ID23912642

P50authorSuleyman Serdar KocaQ88270656
Nevin IlhanQ41900799
P2093author name stringAhmet Isik
Servet Yolbas
Metin Ozgen
Baris Gundogdu
Fatma Akbas
P2860cites workMeasuring disease activity and severity in sclerodermaQ70947293
Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodiesQ72656941
A disease severity scale for systemic sclerosis: development and testingQ73101147
The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trialsQ74267099
Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant miceQ77394043
Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniaeQ80633633
Galectin-3 regulates myofibroblast activation and hepatic fibrosisQ24546358
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3Q24624887
Galectins. Structure and function of a large family of animal lectinsQ28246794
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosusQ29614922
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1.Q32081724
Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblastQ34467951
Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosisQ34501897
Oligosaccharide specificity of galectins: a search by frontal affinity chromatography.Q34837887
The regulation of inflammation by galectin-3.Q34991925
Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-beingQ35169049
Assessment of disease activity.Q35188039
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.Q35550511
Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses.Q35809897
The current state of biomarkers in systemic sclerosisQ35896754
Role of galectin-3 in acetaminophen-induced hepatotoxicity and inflammatory mediator productionQ35969291
Update on indices of disease activity in systemic sclerosisQ36760739
The immunological potential of galectin-1 and -3.Q37343666
Overview of pathogenesis of systemic sclerosisQ37504301
Biomarkers in systemic sclerosisQ37730018
Biomarkers for skin involvement and fibrotic activity in sclerodermaQ37912251
Angiogenesis and vasculopathy in systemic sclerosis: evolving conceptsQ37956146
Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritisQ38497448
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria CommitteeQ39513167
Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosisQ40016270
Role of galectin-3 in human pulmonary fibrosisQ40177839
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosusQ40974327
Galectin 3 and its binding protein in rheumatoid arthritis.Q42451393
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.Q44441787
Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.Q53557883
Preliminary criteria for the classification of systemic sclerosis (scleroderma)Q54165663
SclerodermaQ54165664
Galectin-3 Mediates Aldosterone-Induced Vascular FibrosisQ61187743
Scleroderma (systemic sclerosis): classification, subsets and pathogenesisQ68330753
P433issue2
P304page(s)215-220
P577publication date2013-08-03
P1433published inClinical RheumatologyQ15754927
P1476titleSerum galectin-3 level in systemic sclerosis
P478volume33

Reverse relations

cites work (P2860)
Q47135290Association of Serum Galectin-3 with the Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
Q90639151Early Hyperbaric Oxygen Treatment Attenuates Burn-Induced Neuroinflammation by Inhibiting the Galectin-3-Dependent Toll-Like Receptor-4 Pathway in a Rat Model
Q92312918Galectin 3: an extraordinary multifunctional protein in dermatology. Current knowledge and perspectives
Q90073141Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases
Q57274173Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers
Q38542678Galectin-3 in autoimmunity and autoimmune diseases
Q90640127Galectin-3 orchestrates the histology of mesentery and protects liver during lupus-like syndrome induced by pristane
Q48159180Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.
Q39201281High Expression of Galectin-3 in Patients with IgG4-Related Disease: A Proteomic Approach
Q37339791Prognostic value of plasma galectin-3 levels after aneurysmal subarachnoid hemorrhage
Q41449179Serum galectin-3 levels and delirium among postpartum intensive care unit women.
Q50068427The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients
Q36601648Vesicular Galectin-3 levels decrease with donor age and contribute to the reduced osteo-inductive potential of human plasma derived extracellular vesicles

Search more.